In MIRA's early mouse study, SKNY-1 cut weight without lowering food intake. The company says lean mass held up better than with semaglutide.
Recap by typeshit. Full story at Yahoo Finance.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
3:34
ABC News Australia reports on pressure on the regulator to tighten rules on peptides that haven't been approved.
Some users count clicks on their pens to take smaller doses, hoping to ease side effects and costs. Experts weigh in on whether it's safe.
Loading…